1. Home
  2. QDEL vs ANL Comparison

QDEL vs ANL Comparison

Compare QDEL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

N/A

Current Price

$10.73

Market Cap

989.5M

Sector

Health Care

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$10.80

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QDEL
ANL
Founded
1979
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
989.5M
998.8M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
QDEL
ANL
Price
$10.73
$10.80
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
$15.00
★ $29.50
AVG Volume (30 Days)
★ 2.2M
268.1K
Earning Date
11-03-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 45.35
N/A
EPS
N/A
★ N/A
Revenue
★ $2,730,200,000.00
N/A
Revenue This Year
N/A
$243.83
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$9.92
$0.88
52 Week High
$35.58
$17.25

Technical Indicators

Market Signals
Indicator
QDEL
ANL
Relative Strength Index (RSI) 37.87 46.74
Support Level $10.49 $8.95
Resistance Level $18.15 $11.90
Average True Range (ATR) 1.25 0.99
MACD -0.37 0.25
Stochastic Oscillator 7.55 72.55

Price Performance

Historical Comparison
QDEL
ANL

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: